Business, energy, technology, markets and global industry news from Business News Today

delandistrogene moxeparvovec

PharmaDeviceNews delandistrogene moxeparvovec
Sarepta enrolls non-ambulatory Duchenne patients in ELEVIDYS sirolimus safety study
Pharma & Biotech

Sarepta’s sirolimus gambit: Can enhanced immunosuppression rescue ELEVIDYS for non-ambulatory Duchenne patients?

Sarepta's ELEVIDYS Cohort 8 targets non-ambulatory Duchenne patients with a sirolimus regimen. What the trial design reveals about the path to label restoration.

Read More
Pharma & Biotech

Can Sarepta’s ELEVIDYS redefine Duchenne therapy? Inside the 3-year EMBARK data

Sarepta’s gene therapy ELEVIDYS shows 3-year durability in Duchenne muscular dystrophy. Find out what it means for patients, payers, and global rollout.

Read More
Pharma & Biotech

Can ELEVIDYS meet its promise? Sarepta’s pivotal Duchenne gene therapy trial nears major milestone

Sarepta’s EMBARK 3-year readout could clarify ELEVIDYS’ long-term role in Duchenne care. Find out what’s at stake in this pivotal gene therapy trial.

Read More